Icon Science

CAR T Cell Therapy

Improving chimeric antigen receptor (CAR) T cell therapy with mocravimod – Priothera´s next development target.

hematologic malignancies

Next Development Target

Autologous CAR T cell therapy is an immunotherapy. It uses T cells harvested from the patient, engineered to fight different hematological malignancies and then reinfused into the patient. To improve the treatment outcome and side effects, today’s research focuses on the development of combination treatments and improving the engineering step. Mocravimod has the potential to:

  1. boost the anti-tumor efficacy of CAR T cell therapy by co-locating CAR T cells with malignant cells within lymphoid organs, and
  2. reduce side effects such as the cytokine release syndrome.

Mocravimod as an adjuctive treatment to CAR T cell therapy.

Pre-clinical results have shown a reduction of cytokines and improved tumor reduction when mocravimod was given together with CAR T cell therapy.